Cancer Recurrence clinical trials

Testing a new drug for platinum-resistant ovarian cancer

This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.

PET scan for suspected returning prostate cancer

This trial tests a new imaging drug, 18F-Florastamin, to see if it can better detect prostate cancer that has come back after treatment. You may qualify if you have signs of recurrence and are willing to have a biopsy or additional therapy.

A study of HS-20089 for platinum-resistant ovarian cancer

This trial tests a new drug, HS-20089, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.

A new imaging test for prostate cancer that has come back

This study tests a new imaging drug called Flotufolastat F-18 to find prostate cancer that has returned after treatment. The goal is to see how well and safely it finds the cancer spots, which could help guide next steps.

Adding relatlimab to standard immunotherapy for nasopharyngeal cancer

This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.

Collecting breast cancer tissue to predict recurrence risk

This study builds a “genome atlas” to better predict the chance that breast cancer will come back. It asks participants to share medical information and provide blood and tumor tissue samples, including samples kept in paraffin.

Blood test to predict cervical cancer return after surgery

This trial uses a simple blood test to look for cancer DNA (ctDNA) and HPV DNA after cervical cancer surgery. The goal is to detect any return of the cancer early, so you and your doctor can act quickly.

Zanzalintinib plus paclitaxel for recurrent uterine cancer

This trial combines an experimental pill called zanzalintinib with a standard chemotherapy (paclitaxel) for people with advanced or recurrent high-grade uterine cancer who have already tried platinum-based chemotherapy. The goal is to see if this combination can help shrink or control the cancer better than standard options alone.

Early cancer detection test for colorectal cancer

This trial uses two blood tests (Signatera and Haystack) to look for tiny bits of cancer DNA after surgery, to find out if the cancer comes back as early as possible. People with stage II, III, or IV colorectal cancer who have had or will have surgery to remove their tumor may join.

Registry for adults with UTUC treated with Jelmyto

This registry collects information about adults with upper tract urothelial cancer (UTUC) who received Jelmyto after it was approved. It helps doctors understand outcomes and real-world experience with Jelmyto.

Maintenance Therapy Study for Recurrent Ovarian Cancer

This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.

Blood changes and cancer therapy study

This study looks at why some people develop blood disorders after cancer treatment. It monitors changes in blood cells to better predict and prevent these problems.

Breast cancer chest-wall recurrence quality of life with heat treatment

This trial studies how a special heating radiation treatment (“hyperthermia radiotherapy”) affects quality of life in people whose breast cancer has come back in the chest area. It may help show whether this treatment approach is tolerable and beneficial for everyday well-being.

Early trial of SynKIR-110 for certain ovarian and lung-lining cancers

This Phase 1 study tests SynKIR-110 in people with certain advanced cancers that have come back or continued growing after prior treatments. It aims to find out if the treatment is safe and how the body responds, including early signs of effectiveness.

Combination treatment for advanced solid tumors

This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.

Study of BL-B01D1 plus Keytruda for advanced cervical or endometrial cancer

This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.

Study drug 2X-121 for ovarian cancer that keeps coming back

This Phase 2 trial tests whether 2X-121 can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum chemotherapy. It enrolls people who have had limited prior treatment and can provide a recent or stored tumor sample.

Chemotherapy before surgery for high-risk bile duct cancer

This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.

Testing TI-0093 for advanced HPV-16 positive cancers

This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.

Cancer cell proteins and cervical cancer return risk

This trial looks at whether certain proteins that stop cell death (called inhibitor of apoptosis proteins) in cervical cancer tissue can help predict if the cancer will come back after treatment. It studies patients who had chemoradiation for advanced cervical cancer.

Virus therapy with chemo and immunotherapy for advanced lung cancer

This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.

Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD

Surgery for early prostate cancer spread seen on PSMA PET

This trial studies whether operating on a small, one-sided (unilateral) area of prostate cancer spread in the pelvic lymph nodes—found on a PSMA PET scan—can help control recurrence. It’s meant for people whose PSA is still low and whose spread appears limited on the scan.

Predicting early esophageal cancer return after surgery

This trial uses stored tumor tissue to try to predict if esophageal cancer will come back early after surgery. It is for people who had surgery only (no chemo or radiation) and have been followed for at least 2 years.